Since HCV genotype 3 responds so well to a combination of interferon and Ribavarin, it has been suggested that this patient population may have a similar response to a shorter duration of therapy7, 8, 9. The efficacy of a short course interferon and Ribavarin combination therapy compared to a longer course of therapy has not been compared in the treatment of patients with favorable predictive factors.